Role of HIV membrane in neutralization by two broadly neutralizing antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 48, 2009, Pages 20234-20239

  Alam, S Munir ^a   Morelli, Marco ^b   Dennison, S Moses ^a   Liao, Hua Xin ^a   Zhang, Ruijun ^a   Xia, Shi Mao ^a   Rits Volloch, Sophia ^b,c   Sun, Li ^d   Harrison, Stephen C ^a,b,c   Haynes, Barton F ^a   Chen, Bing ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Xiamen Amoytop Biotech Company Ltd   (China)

Author keywords

gp41; MPER

Indexed keywords

ANTIGEN; EPITOPE; GLYCOPROTEIN GP 41; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANES, ARTIFICIAL; MODELS, MOLECULAR; MUTATION; NEUTRALIZATION TESTS; PROTEIN BINDING; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73949133588     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908713106     Document Type: Article

References (36)

1. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100:4144-4149.
2. Wei X, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422:307-312.
3. Kwong PD, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
4. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
5. Muster T, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
6. Stiegler G, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17:1757-1765.
7. Trkola A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100-1108.
8. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
9. Cardoso RM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
10. Ofek G, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with Its gp41 epitope. J Virol 78:10724-10737.
11. Alam SM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178:4424-4435.
12. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL (2006) Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 22:998-1006.
13. Brown BK, et al. (2007) Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: Role of phosphate-binding subsites. J Virol 81:2087-2091.
14. Biron Z, Khare S, Quadt SR, Hayek Y, Naider F, Anglister J (2005) The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20. Biochemistry 44:13602-13611.
15. Joyce JG, et al. (2002) Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 277:45811-45820.
16. BarbatoG, et al. (2003) Structural analysis oftheepitopeoftheanti- HIVantibody2F5sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 330:1101-1115.
17. Biron Z, Khare S, Samson AO, Hayek Y, Naider F, Anglister J (2002) A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 41:12687-12696.
18. MonteroM,vanHoutenNE,WangX, ScottJK(2008)Themembrane- proximalexternalregion of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72:54-84.
19. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15:690-698.
20. Chan DC, Kim PS (1998) HIV entry and its inhibition. Cell 93:681-684.
21. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
22. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430.
23. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B (2008)Afusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad SciUSA 105:3739-3744.
24. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Krausslich HG (2006) The HIV lipidome: A raft with an unusual composition. Proc Natl Acad Sci USA 103:2641-2646.
25. Rossio JL, et al. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72:7992-8001.
26. Chertova E, et al. (2006) Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80:9039-9052.
27. Yuste E, et al. (2006) Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: Replication, neutralization, and survey of HIV-1-positive plasma. J Virol 80:3030-3041.
28. Zwick MB, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78:3155-3161.
29. Dimitrov AS, Jacobs A, Finnegan CM, Stiegler G, Katinger H, Blumenthal R (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46:1398-1401.
30. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR (2003) Redoxtriggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77:5678-5684.
31. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD (2004) Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: Implications for fusion-inducing conformational changes. J Virol 78:2627-2631.
32. Liao HX, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282.
33. Muñoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 140:315-323.
34. Bess JW, Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO (1997) Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230:134-144.
35. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ (1997) Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230:125-133.
36. Lifson JD, et al. (2004) Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 20:772-787.